Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis
暂无分享,去创建一个
Andrew Hill | A. Hill | Dzintars Gotham | Jonathan Meldrum | Isabelle Erbacher | Christopher Redd | Ryo Harada | D. Gotham | Jonathan Meldrum | C. Redd | Isabelle Erbacher | Ryouhei Harada
[1] N. Ford,et al. Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[3] Lindsay Sarah Ritz,et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. , 2012, Health policy.
[4] E. Montserrat,et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Love. Remuneration guidelines for non-voluntary use of a patent on medical technologies , 2005 .
[6] F. Hulstaert,et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? , 2013, The European Journal of Health Economics.
[7] O. Ukoumunne,et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. , 2012, Health technology assessment.
[8] H. Rugo,et al. A clinician's guide to biosimilars in oncology. , 2016, Cancer treatment reviews.
[9] F. Knaul,et al. Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries , 2011 .
[10] E. Hoen. A victory for global public health in the Indian Supreme Court , 2013 .
[11] Thomas J. Smith,et al. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. , 2014, The Lancet. Oncology.
[12] G. Cooke,et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries , 2015, Journal of virus eradication.
[13] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[14] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[15] Joan Costa-Font,et al. Competition in Off-Patent Drug Markets: Issues, Regulation and Evidence , 2008 .
[16] M. Baccarani,et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] E. Hoen. Access to Cancer Treatment: A study of medicine pricing issues with recommendations for improving access to cancer medication , 2015 .
[18] J. Knoben,et al. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. , 1990, American journal of hospital pharmacy.
[19] J. Bryant,et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. , 2011, Health technology assessment.
[20] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[21] P. Savage,et al. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014 , 2015, British Journal of Cancer.
[22] A. B. Prasad,et al. British National Formulary , 1994 .
[23] Randall Kuhn,et al. Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis , 2012, PLoS medicine.
[24] J. Bergh,et al. A catalyst for change: the European cancer Patient's Bill of Rights. , 2014, The oncologist.
[25] A. Wilson. The British National Formulary. , 1963, The Practitioner.
[26] John Hudson,et al. Generic take-up in the pharmaceutical market following patent expiry A multi-country study , 2000 .
[27] P. Workman,et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.
[28] Breakaway : The global burden of cancer — challenges and opportunities , 2009 .
[29] T. Fojo,et al. Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C Proudlove,et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. , 2010, Health technology assessment.
[31] Richard Sullivan,et al. Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.
[32] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[33] J. Hornaday,et al. Cancer Facts & Figures 2004 , 2004 .
[34] J. Colquitt,et al. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. , 2012, Health technology assessment.
[35] P Barton,et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. , 2011, Health technology assessment.